AnaptysBio, Inc. (NASDAQ:ANAB) Given Consensus Recommendation of “Moderate Buy” by Analysts

AnaptysBio, Inc. (NASDAQ:ANAB) has been assigned an average recommendation of “Moderate Buy” from the twelve ratings firms that are currently covering the stock, Marketbeat Ratings reports. Four research analysts have rated the stock with a hold rating and eight have issued a buy rating on the company. The average 12-month price target among analysts that have covered the stock in the last year is $41.45.

Several equities analysts recently commented on the stock. Truist Financial reduced their target price on shares of AnaptysBio from $30.00 to $20.00 and set a “hold” rating on the stock in a report on Wednesday, December 18th. HC Wainwright cut AnaptysBio from a “buy” rating to a “neutral” rating and reduced their price objective for the company from $52.00 to $19.00 in a research note on Wednesday, December 11th. Wedbush reissued an “outperform” rating and issued a $40.00 target price (down previously from $42.00) on shares of AnaptysBio in a research note on Wednesday, December 11th. BTIG Research lowered AnaptysBio from a “buy” rating to a “neutral” rating in a research report on Monday, December 2nd. Finally, JPMorgan Chase & Co. lowered their price objective on AnaptysBio from $66.00 to $36.00 and set an “overweight” rating for the company in a research report on Thursday, December 19th.

Insider Activity at AnaptysBio

In related news, Director Ecor1 Capital, Llc acquired 6,646 shares of the stock in a transaction on Thursday, January 2nd. The stock was acquired at an average cost of $12.95 per share, for a total transaction of $86,065.70. Following the completion of the acquisition, the director now directly owns 7,880,094 shares of the company’s stock, valued at approximately $102,047,217.30. This represents a 0.08 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 33.70% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. Values First Advisors Inc. purchased a new stake in AnaptysBio in the third quarter worth $49,000. nVerses Capital LLC grew its position in shares of AnaptysBio by 700.0% in the 3rd quarter. nVerses Capital LLC now owns 1,600 shares of the biotechnology company’s stock worth $54,000 after buying an additional 1,400 shares during the period. China Universal Asset Management Co. Ltd. grew its position in shares of AnaptysBio by 81.0% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 5,808 shares of the biotechnology company’s stock worth $195,000 after buying an additional 2,600 shares during the period. Point72 DIFC Ltd increased its stake in shares of AnaptysBio by 680.5% in the 3rd quarter. Point72 DIFC Ltd now owns 6,127 shares of the biotechnology company’s stock worth $205,000 after acquiring an additional 5,342 shares in the last quarter. Finally, Intech Investment Management LLC purchased a new position in AnaptysBio during the 3rd quarter valued at about $229,000.

AnaptysBio Stock Performance

ANAB opened at $17.42 on Friday. The stock has a market capitalization of $530.09 million, a P/E ratio of -2.87 and a beta of -0.02. AnaptysBio has a 12-month low of $12.51 and a 12-month high of $41.31. The stock has a 50-day moving average price of $17.54 and a 200-day moving average price of $27.29.

AnaptysBio (NASDAQ:ANAB) last issued its earnings results on Tuesday, November 5th. The biotechnology company reported ($1.14) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.72) by $0.58. The business had revenue of $30.02 million during the quarter, compared to analyst estimates of $7.92 million. AnaptysBio had a negative return on equity of 287.94% and a negative net margin of 289.75%. On average, equities research analysts predict that AnaptysBio will post -6.08 EPS for the current year.

About AnaptysBio

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.